Nelson Dusetti: Nicolas Fraunhoffer and Brice Chanez have been awarded funding from Canceropôle Provence-Alpes-Côte d’Azur
Nelson Dusetti, Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM, shared a post on LinkedIn:
“We are thrilled to announce that Nicolas Fraunhoffer Ph.D., molecular biologist at CRCM – Centre de Recherche en Cancérologie de Marseille, and Brice Chanez, oncologist at Institut Paoli-Calmettes, both from the Pancreatic Cancer Team, have been awarded funding from Canceropôle Provence-Alpes-Côte d’Azur. This support emphasizes the importance of fostering young researchers and clinicians committed to advancing translational research.
The funded project aims to deepen our understanding of chemoresistance mechanisms and enhance predictive models for chemotherapy responses. This initiative holds great potential for improving personalized treatment strategies for pancreatic cancer.
We extend our sincere thanks to Canceropôle Provence-Alpes-Côte d’Azur for driving such impactful efforts and for supporting the next generation of scientific and medical talent dedicated to translational research in pancreatic cancer.
Nelson Dusetti is the Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023